Bristol Myers Squibb

Bristol Myers Squibb is a biopharmaceutical company headquartered in New Jersey. The company markets and sells pharmaceutical products and biologics, including immuno-oncology, cardiovascular, and autoimmune medicines. Christopher Boerner is the Chairman and CEO of this medical company. Since Bristol Myers Squibb relies heavily on laboratories, biologics manufacturing, cell therapy, manufacturing of pharmaceutical products, and regulated water systems, water management practices are related to its ESG performance.

BMS completed the installation of a water management system at its major water users' facilities. In 2023, the company conducted a water analysis to establish the water consumption of its largest sites. Furthermore, the company's six (6) highest water-consuming facilities gained access to cloud-based technologies and smart meters. These digital tools enable BMS to monitor and detect deviations in time, helping reduce water consumption significantly.

Water risk assessments are embedded in the company's strategic planning process. For example, BMS utilizes the WRI Aqueduct tool to determine the water risks associated with its business operations, identify water stress regions, and incorporate the findings into its Business Continuity Management programs. This way, the company ensures that it can continue functioning despite water-related challenges.

Finally, one of BMS's significant accomplishments in this area involves the company's initiative to replace animal testing with synthetic technologies. In 2025, for instance, the company completed nearly 9,000 water tests at its New Brunswick and Cruiserath facilities using a synthetic alternative to horse blood extract. This innovation reduced the use of the horse blood extract by 99% at the New Brunswick facility in 2025. This shows how the company's water testing procedures support its sustainability goals.